NCT02361775

Brief Summary

Level I randomized prospective outcomes study comparing two groups of patients. One group will receive Dilaudid patient controlled analgesia (PCA) post-operatively. The other will receive an ultrasound guided paravertebral block with indwelling paravertebral catheter with an infusion of 0.2% Ropivicaine post-operatively and a PCA.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P50-P75 for early_phase_1

Timeline
Completed

Started Jul 2012

Typical duration for early_phase_1

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2012

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2014

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

February 3, 2015

Completed
9 days until next milestone

First Posted

Study publicly available on registry

February 12, 2015

Completed
Last Updated

February 12, 2015

Status Verified

February 1, 2015

Enrollment Period

2.3 years

First QC Date

February 3, 2015

Last Update Submit

February 11, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Maximum NRS Pain score

    pain at movement or maximum in first 24 hours after surgery

    0-24 hours after surgery

Secondary Outcomes (2)

  • total opioid use

    the first 5 days after surgery

  • length of stay

    time until patient is ready to be discharged or is discharged, expected 5 days

Other Outcomes (1)

  • the number of patients with presence of nausea and vomiting

    the first 5 days postoperatively

Study Arms (2)

Paravertebral catheter

EXPERIMENTAL

a paravertebral catheter is placed and an elastomeric pump is connected to infuse 0.2% ropivacaine postoperatively

Device: Paravertebral catheterDrug: RopivacaineDevice: Elastomeric Pump

IV PCA

ACTIVE COMPARATOR

opioid PCA consisting of hydromorphone is connected to patient in the post anesthesia care unit

Device: opioid iv pca

Interventions

A catheter is placed ultrasound guided at the T5 paravertebral level

Paravertebral catheter

opioid pca consisting of hydromorphone

IV PCA

0.2% ropivacaine infused through paravertebral catheter

Also known as: Naropin
Paravertebral catheter

Elastomeric pump connected to paravertebral catheter

Also known as: On Q
Paravertebral catheter

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • All patients undergoing elective VATS.

You may not qualify if:

  • Previous difficult airway or multiple previous intubations
  • History of myasthenic syndrome
  • Systemic infection
  • Pre-existing sensory deficit
  • PT \>14 or PTT \>40 sec
  • Platelet count less than 50,000
  • Creatinine \> 1.5
  • Allergy to local anesthetics
  • Patients who remain intubated for one week after surgery or who are unable to provide information as to their feelings of pain post-operatively for the first week post-operatively
  • Use of a spinal or epidural anesthetic for surgery
  • Daily use of opioid for more than a week
  • Lack of patient cooperation
  • Contraindication to regional anesthesia
  • Infection at injection site
  • Inability to guarantee sterile equipment or sterile conditions for the block
  • +7 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Acute Pain

Interventions

Ropivacaine

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 3, 2015

First Posted

February 12, 2015

Study Start

July 1, 2012

Primary Completion

October 1, 2014

Study Completion

October 1, 2014

Last Updated

February 12, 2015

Record last verified: 2015-02